Investors on the quest for market-beating returns often employ the strategy of stock picking. Making informed choices in stocks can greatly amplify your wealth.
As of close of business last night, Neurocrine Biosciences, Inc’s stock clocked out at $140.95, down -1.87% from its previous closing price of $143.64. In other words, the price has decreased by -$1.87 from its previous closing price. On the day, 0.99 million shares were traded. NBIX stock price reached its highest trading level at $143.18 during the session, while it also had its lowest trading level at $140.56.
Ratios:
To gain a deeper understanding of NBIX’s stock, we examine its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 12.61 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 23.70. For the most recent quarter (mrq), Quick Ratio is recorded 3.27 and its Current Ratio is at 3.38. In the meantime, Its Debt-to-Equity ratio is 0.16 whereas as Long-Term Debt/Eq ratio is at 0.14.
Upgrades & Downgrades
In the most recent recommendation for this company, Citigroup on October 21, 2025, initiated with a Buy rating and assigned the stock a target price of $175.
On July 21, 2025, Truist started tracking the stock assigning a Buy rating and target price of $163.
On July 10, 2025, Goldman started tracking the stock assigning a Buy rating and target price of $182.Goldman initiated its Buy rating on July 10, 2025, with a $182 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Dec 15 ’25 when Norwalk Leslie V sold 5,000 shares for $152.23 per share. The transaction valued at 761,144 led to the insider holds 7,429 shares of the business.
Norwalk Leslie V sold 1,190 shares of NBIX for $184,558 on Dec 16 ’25. The Director now owns 6,239 shares after completing the transaction at $155.09 per share. On Dec 15 ’25, another insider, Norwalk Leslie V, who serves as the Director of the company, bought 11,250 shares for $155.11 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, NBIX now has a Market Capitalization of 14053517312 and an Enterprise Value of 13418418176. As of this moment, Neurocrine’s Price-to-Earnings (P/E) ratio for their current fiscal year is 33.66, and their Forward P/E ratio for the next fiscal year is 19.91. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 0.55. For the stock, the TTM Price-to-Sale (P/S) ratio is 5.24 while its Price-to-Book (P/B) ratio in mrq is 4.68. Its current Enterprise Value per Revenue stands at 5.002 whereas that against EBITDA is 23.541.
Stock Price History:
The Beta on a monthly basis for NBIX is 0.28, which has changed by 0.041926622 over the last 52 weeks, in comparison to a change of 0.17673707 over the same period for the S&P500. Over the past 52 weeks, NBIX has reached a high of $160.18, while it has fallen to a 52-week low of $84.23. The 50-Day Moving Average of the stock is -3.97%, while the 200-Day Moving Average is calculated to be 7.80%.
Shares Statistics:
It appears that NBIX traded 994.99K shares on average per day over the past three months and 1003720 shares per day over the past ten days. A total of 99.70M shares are outstanding, with a floating share count of 97.07M. Insiders hold about 2.65% of the company’s shares, while institutions hold 98.34% stake in the company. Shares short for NBIX as of 1765756800 were 3939195 with a Short Ratio of 3.96, compared to 1763078400 on 3355702. Therefore, it implies a Short% of Shares Outstanding of 3939195 and a Short% of Float of 5.2600004.
Earnings Estimates
. The current market rating for Neurocrine Biosciences, Inc (NBIX) reflects the collective analysis of 15.0 analysts closely monitoring its performance.The consensus estimate for the next quarter is $1.99, with high estimates of $2.45 and low estimates of $1.77.
Analysts are recommending an EPS of between $7.58 and $6.47 for the fiscal current year, implying an average EPS of $6.92. EPS for the following year is $9.17, with 16.0 analysts recommending between $11.05 and $7.14.
Revenue Estimates
In. The current quarter, 23 analysts expect revenue to total $803.13M. It ranges from a high estimate of $828.3M to a low estimate of $760.8M. As of. The current estimate, Neurocrine Biosciences, Inc’s year-ago sales were $627.7MFor the next quarter, 23 analysts are estimating revenue of $773.97M. There is a high estimate of $848.49M for the next quarter, whereas the lowest estimate is $722.7M.
A total of 24 analysts have provided revenue estimates for NBIX’s current fiscal year. The highest revenue estimate was $2.88B, while the lowest revenue estimate was $2.8B, resulting in an average revenue estimate of $2.85B. In the same quarter a year ago, actual revenue was $2.36BBased on 23 analysts’ estimates, the company’s revenue will be $3.4B in the next fiscal year. The high estimate is $3.65B and the low estimate is $3.11B.
